Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2007; 13(48): 6553-6557
Published online Dec 28, 2007. doi: 10.3748/wjg.v13.i48.6553
Published online Dec 28, 2007. doi: 10.3748/wjg.v13.i48.6553
Table 4 Reported toxicity by 31 patients n (%)
| Toxicity | Grade 1-2 | Grade 3-4 |
| Neutropenia | 7 (22.5) | 3 (10) |
| Anemia | 8 (26) | 2 (6.5) |
| Thrombocytopenia | 5 (16) | 2 (6.5) |
| Oral stomatitis | 7 (22.5) | 1 (3) |
| Nausea/vomiting | 3 (10) | 2 (6.5) |
| Diarrhea | 3 (10) | 1 (3) |
| Hand-foot syndrome | 5 (16) | 0 |
| Hepatic dysfunction | 3 (10) | 0 |
| Peripheral neuropathy | 3 (10) | 0 |
- Citation: Lorenzo GD, Rea A, Carlomagno C, Pepe S, Palmieri G, Labianca R, Chirianni A, Stefano AD, Esposito V, Placido SD, Montesarchio V. Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study. World J Gastroenterol 2007; 13(48): 6553-6557
- URL: https://www.wjgnet.com/1007-9327/full/v13/i48/6553.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i48.6553